Form 4: Fate Therapeutics Director Granted 55,000 Stock Options Under Compensation Policy

A director at Fate Therapeutics, Neelufar Mozaffarian, was granted 55,000 stock options with an exercise price of $1.32, as part of the company's non-employee director compensation policy.

Summary

• Neelufar Mozaffarian, a Director at Fate Therapeutics Inc. (FATE), was granted 55,000 stock options.
• The options have an exercise price of $1.32 per share.
• The transaction date for this grant was May 29, 2025.
• These options were granted pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy.
• The grant occurred on the date of the Issuer's Annual Meeting of Stockholders.
• The options will vest and become exercisable on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders.
• Vesting is contingent upon Ms. Mozaffarian's continued service on the Issuer's Board of Directors.
• The options have an expiration date of May 29, 2035.
• Following this transaction, Ms. Mozaffarian directly beneficially owns 55,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of stock options to a director is a standard practice for aligning interests and retaining talent, indicating stable corporate governance and a commitment to long-term incentives. There are no negative surprises or adverse events reported.

Positives

• The grant of stock options aligns the interests of the director, Neelufar Mozaffarian, with those of the shareholders, as the options gain value if the stock price increases.
• This transaction is part of a pre-established compensation policy, indicating a structured approach to director remuneration and retention.

Negatives

• The issuance of new stock options could lead to minor dilution for existing shareholders if exercised, although the amount is relatively small in the context of a public company.

Risks

• The value of the granted stock options is subject to the future performance of Fate Therapeutics' stock price; if the stock price does not exceed the exercise price of $1.32, the options may expire worthless.
• Continued service on the Board of Directors is required for the options to vest, posing a risk to the recipient if service is terminated prior to vesting dates.

Future Outlook

The stock options granted to the director are set to vest on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service, indicating a future milestone for the director's equity compensation.

Industry Context

This Form 4 filing reflects a routine equity compensation practice common across publicly traded companies, particularly in the biotechnology sector, to attract and retain qualified board members. Such grants are standard mechanisms for aligning director incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard practice in the biotechnology and pharmaceutical industries, comparable to compensation structures at companies like Gilead Sciences, Amgen, or Biogen, which often use equity to incentivize long-term commitment and performance.
• The vesting schedule, tied to continued service and future annual meetings, is typical for director equity awards, ensuring ongoing engagement and oversight.
• The exercise price of $1.32, while specific to this grant, is consistent with options granted at fair market value on the grant date, a common industry benchmark for such awards.

Corporate Governance

Related Party Transactions

• The grant of 55,000 stock options to Neelufar Mozaffarian, a director of Fate Therapeutics, constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options, while a form of compensation, can lead to minor dilution if exercised, but also aims to align the director's interests with long-term shareholder value creation.
• Employees: No direct impact mentioned, but consistent compensation policies for leadership can contribute to overall company stability and morale.
• Board of Directors: The compensation policy helps attract and retain qualified directors, ensuring strong governance and strategic oversight.

Next Steps

• The stock options are scheduled to vest on the earlier of May 29, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on the director's continued service.

Key Dates

Keywords

Fate Therapeutics, FATE, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Grant, Biotechnology, Pharmaceuticals